ImmunityBio Investor Relations Material
Latest events
Investor Day 2025
ImmunityBio
Q2 2025
5 Aug, 2025
Q1 2025
12 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from ImmunityBio Inc
Access all reports
ImmunityBio, Inc. is a biotechnology company focused on developing innovative immunotherapies and cell therapies to treat cancer and infectious diseases. The company’s pipeline leverages platforms such as T-cell and natural killer (NK) cell-based therapies, along with vaccine technologies, to enhance the immune system’s ability to target and eliminate disease. The company is headquartered in Culver City, California, and its shares are listed on the NASDAQ.
Key slides for ImmunityBio Inc
Investor Day 2025
ImmunityBio Inc
Investor Day 2025
ImmunityBio Inc
Latest articles
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
Ticker symbol
IBRX
Country
🇺🇸 United States